FMNT was also proven to downregulate the expression of key pro-angiogenic factors such as VEGF and matrix metalloproteinases in colon cancer cells, and to inhibit angiogenesis and tumor cell invasion, thereby supporting its use in advanced and metastatic colon therapies (Auyeung et al., 2012). The gene discussed is VEGFA; the disease is neoplasm.